Breaking News, Trials & Filings

GSK, Theravance Begin Phase II COPD Trial

GlaxoSmithKline and Theravance have initiated a Phase IIb study to evaluate the efficacy and safety of GSK961081 (‘081), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Theravance have initiated a Phase IIb study to evaluate the efficacy and safety of GSK961081 (‘081), in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The ‘081 compound is an investigational drug within the inhaled bifunctional muscarinic antagonist-beta2 agonist (MABA) program that Theravance licensed to GSK in 2005 under a strategic alliance. Approximately 425 patients with moderate/severe COPD will be randomized in a multi-center, double-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters